1
Clinical Trials associated with SII inactivated Salk polio vaccine (adsorbed)(Serum Institute of India Pvt Ltd.)A Phase III, Double Blind, Randomized, Active Controlled Study to Evaluate Safety and Immunogenicity of Inactivated Adjuvanted Polio Vaccine in Comparison With Licensed Inactivated Poliovirus Vaccine
This Phase III study has been designed to compare the SII Inactivated Salk Polio Vaccine (Adsorbed) with Sii licensed IPV by testing the vaccine in infants (three doses administered 4 weeks apart, starting at 6-8 weeks of age) in order to demonstrate the non-inferiority in the induction of specific poliovirus neutralizing antibody (PVNA) to poliovirus type 1, type 2 and type 3 by these vaccines. The study will also evaluate lot-to-lot consistency in the manufacture of SII Inactivated Salk Polio Vaccine (Adsorbed) by demonstrating equivalence in the induction of PVNA across three production lots.
100 Clinical Results associated with SII inactivated Salk polio vaccine (adsorbed)(Serum Institute of India Pvt Ltd.)
100 Translational Medicine associated with SII inactivated Salk polio vaccine (adsorbed)(Serum Institute of India Pvt Ltd.)
100 Patents (Medical) associated with SII inactivated Salk polio vaccine (adsorbed)(Serum Institute of India Pvt Ltd.)
100 Deals associated with SII inactivated Salk polio vaccine (adsorbed)(Serum Institute of India Pvt Ltd.)